LONDON and PHILADELPHIA - April 8, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to extend an open invitation for colleagues and investors to attend the Company's 2026 Science Day: "The Next Chapter of pre|CISION."

The Avacta Science Day event for investors will take place in Central London on May 6, 2026 commencing at 10.30 AM, at the Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA. Avacta team members will share presentations on the company's scientific achievements and our aspirations, to be followed by a reception for attendees.

Attendance will be limited by the capacity of the venue, so attendees will be accepted on a first come, first served basis. Investors wishing to attend should please indicate interest by email at investors@avacta.com.

For investors unable to attend in person, the event will be professionally recorded and the video made available on the Avacta website in due course.

Attachments

  • Original document
  • Permalink

Disclaimer

Avacta Group plc published this content on April 08, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 08, 2026 at 06:10 UTC.